Loading...
Please wait, while we are loading the content...
Similar Documents
The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients.
| Content Provider | Europe PMC |
|---|---|
| Author | Huang, Chun-Feng Mao, Tso-Yen Hwang, Shinn-Jang |
| Copyright Year | 2023 |
| Abstract | PurposeDiabetes increases the risk of fragility fractures. As a result, when choosing a diabetes treatment, whether the drug affects bone density should be taken into account. The goal of this study was to determine how switching from dipeptidyl peptidase-4 inhibitors (DPP-4i) to glucagon-like peptide-1 receptor agonists (GLP-1RA) influenced bone mineral density (BMD) in diabetic patients.Patients and MethodsIn this retrospective cohort study, diabetic patients with osteoporosis or osteopenia who used DPP-4i but not anti-osteoporosis medications were divided into two groups: those who switched to GLP-1RA (n = 132) and those who did not (control group, n = 133). We compared changes in glycemic control and BMD with and without conversion from DPP-4i to GLP-1RA.ResultsPrior to switching, there was no difference between the groups in terms of age, gender, glycosylated hemoglobin (HbA1c), or BMD. HbA1c was 8.7% in the participants (mean age 62.7 years, 17.4% female). Despite the fact that there was no difference in femoral neck BMD, the GLP-1RA group had a greater decrease in lumbar spine BMD (−0.028 g/cm2 versus −0.019 g/cm2, p = 0.041) than the control group. Furthermore, HbA1c levels in the GLP-1RA-treated group were considerably lower than in the control group (7.5% versus 8.0%, p = 0.027).ConclusionWhile switching to GLP-1RA improves glycemic control, it appears to have a less favorable effect on bone density than continuing DPP-4i. More research is needed, however, to determine whether diabetic patients with low bone density should be switched from DPP-4i to GLP-1RA. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9843232&blobtype=pdf |
| Page Count | 6 |
| Journal | Diabetes, Metabolic Syndrome and Obesity [Diabetes Metab Syndr Obes] |
| Volume Number | 16 |
| PubMed Central reference number | PMC9843232 |
| PubMed reference number | 36760582 |
| e-ISSN | 11787007 |
| DOI | 10.2147/dmso.s389964 |
| Language | English |
| Publisher | Dove |
| Publisher Date | 2023-01-11 |
| Access Restriction | Open |
| Rights License | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Huang et al. |
| Subject Keyword | bone mineral density diabetes dipeptidyl peptidase-4 inhibitor glucagon-like peptide-1 receptor agonist osteoporosis |
| Content Type | Text |
| Resource Type | Article |
| Subject | Internal Medicine Pharmacology |
